PharmaShots | Incisive News in 3 Shots

Subscribe Now

HER2+ Early Breast Cancer

Roche's Kadcyla (trastuzumab emtansine) Receives CHMP's Recommendation for Approval as an Adjuvant Treatment for Patients with HER2+ eBC with Residual Invasive Disease After Neoadjuvant Treat

Roche's Kadcyla (trastuzumab emtansine) Receives CHMP's Recommendation for Approval as an Adjuvant Treatment for Patients with HER...

November 15, 2019

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us